For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$376.04
Thesis
Amgen is a diversified large-cap biopharma using its scale and commercial reach to push into the obesity market. Its monthly-dosed incretin candidate offers a differentiated profile against an established injectable franchise.
Catalysts
- MariTide late-stage obesity readouts
- Label expansion into cardiometabolic indications
- Biosimilar and base-business cash generation funding the pipeline
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.